<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Protalix BioTherapeutics Inc. | Company News & Executive Profiles - PLX | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/protalix+biotherapeutics+inc..html?i=3]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Protalix BioTherapeutics Inc.]]></description>
	<s:counts start="0" returned="5" found="5" />
	<language>en-us</language>
	<item>
		<title><![CDATA[BioMed News Bytes: Protalix, Soligenix]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F166733-biomed-news-bytes-protalix-soligenix%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Havrilla submits: On 10/15/09, Protalix BioTherapeutics (AMEX: PLX) announced positive top-line results of a pivotal Phase 3 study of its lead drug candidate, UPLYSO Taliglucerase Alfa in treatment naïve patients diagnosed with Gaucher disease.  In the study, UPLYSO met its primary endpoint of mean reduction in spleen volume...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 15 Oct 2009 08:05:49 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/mike+havrilla.html"><![CDATA[Mike Havrilla]]></category>
		<category domain="http://resources.bnet.com/topic/protalix+biotherapeutics+inc..html"><![CDATA[Protalix BioTherapeutics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/vulcan+energy+corp..html"><![CDATA[Vulcan Energy Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PLX</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PLX</category>
		<category domain="tickers">PLX,PLX</category>
	</item>
	<item>
		<title><![CDATA[Protalix Wins Orphan Drug Status for Gaucher Disease Treatment]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F160778-protalix-wins-orphan-drug-status-for-gaucher-disease-treatment%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   On Tuesday, Protalix BioTherapeutics, Inc. PLX announced that the U.S. Food and Drug Administration FDA has granted orphan drug designation to prGCD for the treatment of Gaucher disease, an enzyme disorder that can cause liver and neurological problems. The drug is currently being evaluated in a...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 10 Sep 2009 02:10:18 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/us+market.html"><![CDATA[US Market]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/protalix+biotherapeutics+inc..html"><![CDATA[Protalix BioTherapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PLX</category>
		<category domain="tickers">PLX</category>
	</item>
	<item>
		<title><![CDATA[Why Would an Insider Be Selling Protalix Shares Now of All Times?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F159575-why-would-an-insider-be-selling-protalix-shares-now-of-all-times%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Shlomi Cohen submits:  Among the shares in Israeli companies in my portfolio tracked by "Globes", Protalix Biotherapeutics Inc. (AMEX:PLX) can be expected to attract the most attention over the coming weeks. It is a rare situation in our area - a biotech company that grew from an Office of...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 02 Sep 2009 05:01:01 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/shlomi+cohen.html"><![CDATA[Shlomi Cohen]]></category>
		<category domain="http://resources.bnet.com/topic/genzyme+corp..html"><![CDATA[Genzyme Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/protalix+biotherapeutics+inc..html"><![CDATA[Protalix BioTherapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GENZ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PLX</category>
		<category domain="tickers">GENZ,PLX</category>
	</item>
	<item>
		<title><![CDATA[Why I'm Buying Protalix]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F156983-why-i-m-buying-protalix%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Shlomi Cohen submits:  I'm adding Protalix Biotherapeutics Inc. (AMEX:PLX) to my portfolio at the expense of half my holding in Fundtech (Nasdaq: FNDT), although I continue to believe in Fundtech as a special niche company in financial software. I'm getting into biotechnology again, which, as is well known, is...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 19 Aug 2009 01:41:04 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/shlomi+cohen.html"><![CDATA[Shlomi Cohen]]></category>
		<category domain="http://resources.bnet.com/topic/protalix+biotherapeutics+inc..html"><![CDATA[Protalix BioTherapeutics Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PLX</category>
		<category domain="tickers">PLX</category>
	</item>
	<item>
		<title><![CDATA[Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Sept_8/ai_n30883796]]></link>
		<description><![CDATA[CARMIEL, Israel -- Protalix BioTherapeutics, Inc. (Amex: PLX), today announced that its board of directors has set the close of business on October 2, 2008, as the record date for shareholders entitled to receive notice of, and to vote at, the Company's 2008 Annual Meeting of Shareholders. It is currently...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 08 Sep 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/israel.html"><![CDATA[Israel]]></category>
		<category domain="http://resources.bnet.com/topic/protalix+biotherapeutics+inc..html"><![CDATA[Protalix BioTherapeutics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/shareholder.html"><![CDATA[shareholder]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PLX</category>
		<category domain="tickers">PLX</category>
	</item>
</channel>
</rss>
